Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
Metric Value Shares sold (direct) Transaction value Post-transaction shares (direct) Post-transaction value (direct ownership) $8.11 million Transaction value based on SEC Form 4 reported price ($82.48); post-transaction value based on Jan. 20, 2026 market close ($82.48). How does the size of this sale compare to Dr. Molina's historical open-market transactions? This 9,514-share sale is the largest direct open-market sale by Dr. Molina to date, exceeding his previous sell-only transaction maximum of 2,712 shares. Were any derivative instruments, options, or indirect entities involved in this transaction? No, the filing shows only direct common stock was sold, with no participation by trusts or other indirect entities, and no derivative or option activity was reported. Metric Value Market capitalization $5.11 billion Revenue (TTM) $209.22 million Net income (TTM) $45.91 million *1-year price change * 1-year price change calculated using Jan. 3
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- J&J Expands New Drug Portfolio With Icotyde's FDA Approval [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (PTGX) had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an "outperform" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an "overweight" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a "buy" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $113.00 to $119.00. They now have an "overweight" rating on the stock.MarketBeat
PTGX
Earnings
- 2/25/26 - Miss
PTGX
Sec Filings
- 3/24/26 - Form 144
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- PTGX's page on the SEC website